Thanks Mysterium: i havent posted on Investors Hangout in a
Thanks Mysterium: i havent posted on Investors Hangout in a long time. Cant wait to see what happens, as with FDA clearance ADMD becomes the new biotech Y-90 cancer therapy company in the world.
Things like this rarely happen in the Penny Market, with developed biotechnologies that are this complex ...this isnt some new kind of bandages or ancillary health product they are coming to market with: this is combating cancer at the molecular level ...the highest stakes of health in the world of medicine.
May they get the FDA approval ---!
Vivos Inc. (RDGL) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Brixton Metals Expands Thorn Project with New Mineral Claims Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) has expanded its footprint at the Thorn Project, securing a 100% interest in mineral claims covering 6,446 hectares. These claims, which were previously outside Brixton’s control, sit northwest of the well-known Golden Bear Mine and add ground the company...
Continue Reading
Diving headfirst into the grumbles of this healthcare whirlwind we call Nutex Health. They've set the table to drop their Q2 financials on August 6, right after the bell, followed by a chat with investors the next morning. We're talking bumper-to-bumper business news here, and everyone with a slice in NASDAQ: NUTX better have their ears pricked. Nutex Health: A Mixed Bag...
Continue Reading
Arvore Partners LP Declares Monthly Distribution for October Arvore Partners LP is thrilled to share details about the declaration of its monthly distribution for October. This distribution amounts to $687,365, which translates to an impressive 9.06% annualized yield for its unitholders, marking a 7% increase from the previous month. This consistent growth highlights...
Continue Reading
An Overview of Marathon Petroleum's Earnings Expectations Marathon Petroleum (NYSE: MPC) is gearing up for its quarterly earnings announcement. Investors should prepare for necessary insights leading up to the release of this important announcement. Analysts predict a solid earnings per share (EPS) of $3.23 for the upcoming quarter. While it’s crucial for the company to...
Continue Reading
Transforming Male Infertility Research with PacBio's Revio MENLO PARK, Calif. — PacBio (NASDAQ: PACB), a leading name in sequencing solutions, is launching an exciting collaboration with the University Hospital of Münster. This partnership is set to leverage long-read whole genome sequencing to significantly advance research in male infertility and rare diseases....
Continue Reading
